Science-based products and services provider DuPont said on Tuesday it will commission a plant at Baddi in Himachal Pradesh to manufacture animal and human healthcare solutions, seeking to earn Rs 50 crore (Rs 500 million) revenue from the business in the next 2-3 years.
"The plant is in the testing stage... It would commence production by the end of this month," DuPont India President and CEO Balvinder S Kalsi told reporters in New Delhi on Tuesday.
"The initiative makes sense in the wake of spread of epidemic like avian flu. The company will manufacture a range of bio-security chemicals including cleaners, disinfectants and sanitisers at the plant to prevent such diseases from mutating to humans," DuPont Animal Health Solutions Regional Marketing Manager (Asia Pacific) Dipal Parikh said.
The
plant is capable to meet requirements of domestic as well as overseas market, Parikh said. DuPont India, a subsidiary of US-based E I du Pont de Nemours and Company, earlier imported the products from its plant in the United Kingdom.
The products from the Baddi plant would be customised to suit needs of Indian farmers and would be marketed in the country through its channel partner Pfizer. DuPont India is a $400 million company and endeavours to maintain a year-on-year growth of over 20 per cent.
It expects to clock Rs 16-17 crore (Rs 160 to Rs 170 million) this fiscal, Kalsi said. The bio-security business is expected to yield Rs 30-50 crore (Rs 300-500 million) revenue in 2-3 years time, he said.
The company is present in agriculture, automotive paints, construction, safety and polymer segments in the country.